Condition: Prostate Cancer · Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.
This description comes directly from the study's public registry record.
Wenliang Wang · +86-0518-82342973 · wenliang.wang@hengrui.com
Qi Zhang · +86-021-60453139 · qi.zhang@hengrui.com
Always discuss trial participation with your own doctor first.
| Nanjing Drum Tower Hospital | Nanjing, Jiangsu, China | Recruiting |
| Tianjin Medical University Cancer Institute and Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07230106